Valuation: HLS Therapeutics Inc.

Market Cap 86.34M 75.29M 71.09M 64.56M 121M 8.29B 121M 852M 329M 4.21B 324M 317M 13.55B P/E 2026 *
-13.5x
P/E 2027 * -39.9x
Enterprise Value 86.34M 75.29M 71.09M 64.56M 121M 8.29B 121M 852M 329M 4.21B 324M 317M 13.55B EV / Sales 2026 *
1.48x
EV / Sales 2027 * 1.33x
Free-Float
99.45%
Yield 2026 *
-
Yield 2027 * -
1 day-2.01%
1 week+0.26%
Current month+4.27%
1 month+0.26%
3 months-8.86%
6 months-11.14%
Current year-18.88%
1 week 3.9
Extreme 3.9
4.2
1 month 3.56
Extreme 3.56
4.2
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/26 Buy

Compliance Officer

2,000 0.0064%
1/9/26 Buy

Chief Financial Officer

2,000 0.0064%
28/8/26 TaxCompany -2,000 0.0064% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.01%+0.26%-31.40%-21.80% 86.34M
-0.56%-0.78%+26.74%+104.70% 102B
-0.42%-3.92%+50.21%+155.62% 52.42B
+2.00%-3.04%-13.56%+235.53% 20.85B
-1.61%-2.39%-12.78%-10.97% 7.88B
-0.19%-0.61%-38.37%-36.77% 6.83B
-0.19%-4.19%-4.96%+15.34% 6.41B
-0.07%-2.21%-19.07%-31.26% 5.97B
-1.57%-1.63%-3.72%+17.24% 4.94B
-2.92%+0.71%+9.85%+8.82% 3.79B
Average -0.75%-1.83%-3.71%+43.64% 21.12B
Weighted average by Cap. -0.34%-1.71%+21.71%+110.99%

Financials

2026 *2027 *
Net sales 58.44M 50.96M 48.12M 43.69M 81.86M 5.61B 82.21M 576M 222M 2.85B 220M 215M 9.17B 65.03M 56.7M 53.54M 48.62M 91.09M 6.24B 91.47M 641M 247M 3.17B 244M 239M 10.21B
Net income -5.47M -4.77M -4.5M -4.09M -7.66M -525M -7.69M -53.94M -20.82M -267M -20.55M -20.09M -859M -2.16M -1.89M -1.78M -1.62M -3.03M -208M -3.04M -21.35M -8.24M -106M -8.13M -7.95M -340M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
18/09/26 CAD 3.910 -2.01% 27,494
17/09/26 CAD 3.990 -0.99% 8,502
16/09/26 CAD 4.030 -1.47% 1,618
15/09/26 CAD 4.090 -1.45% 241,861
14/09/26 CAD 4.150 +6.41% 54,491
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.791USD
Average target price
5.286USD
Spread / Average Target
+89.38%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!